Effect of Additional Clostridium butyricum on the Intestinal Flora of Chronic Hepatitis B Patients Treated with Entecavir

被引:5
|
作者
Lu, Yu-Xia [1 ]
Chang, Yi-Zhong [1 ]
Liang, Ping [2 ]
Yang, Chang-Qing [1 ]
机构
[1] Tongji Univ, Tongji Hosp, Inst Digest Dis, Dept Infect Dis,Dept Gastroenterol & Hepatol,Sch, 389 Xin Cun Rd, Shanghai 200065, Peoples R China
[2] Tongji Univ, Tongji Hosp, Dept Lab Med, Sch Med, 389 Xin Cun Rd, Shanghai 200065, Peoples R China
基金
中国国家自然科学基金;
关键词
Chronic viral hepatitis B; Clostridium butyricum; Entecavir; Intestinal microflora; GUT-LIVER AXIS; MICROBIOTA; CIRRHOSIS; PATHOGENESIS; DISEASES;
D O I
10.1007/s40121-021-00463-1
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Introduction To explore the influence of intestinal flora on the occurrence, development and antiviral therapy of chronic hepatitis B (CHB), 16S rDNA amplification sequencing was performed to investigate the intestinal flora in CHB patients treated with entecavir (ETV) and Clostridium butyricum (CB). Methods CHB patients were divided into the ETV group (treatment with ETV alone) and ETV + CB group (treatment with ETV and CB). After 8-week treatment, feces samples were collected and processed for 16S rDNA amplicon sequencing; blood samples were collected for the biochemical, immunologic and virologic evaluations, which were compared between groups. Results ETV treatment for 8 weeks significantly decreased the serum levels of alanine aminotransferase (ALT), interleukin-6 (IL-6), IL-8, tumor necrosis factor-alpha (TNF-alpha) and HBV DNA compared to those before treatment, but there were no marked differences between the ETV group and ETV + CB group. The intestinal flora changed significantly in the CHB patients after ETV + CB treatment: there were marked differences in 13 unique species before treatment and 4 unique species after ETV + CB treatment; at the phylum level, the top five bacteria with significant difference between patients before treatment and ETV + CB patients were Firmicutes, Actinobacteria, Cyanobacteria, Euryarchaeota and Synergistetes. There were significant differences in 25 unique species in the ETV group and 4 unique species in the ETV + CB group; at the phylum level, the top five bacteria with significant difference between ETV patients and ETV + CB patients were Actinobacteria, Fusobacteria, Proteobacteria, Saccharibacteria and Synergistetes. Conclusion ETV treatment improves the serum biochemical, immunologic and virologic variables, but additional CB fails to further improve these variables. Of note, additional CB affects the intestinal flora in the CHB patients treated with ETV.
引用
收藏
页码:1519 / 1530
页数:12
相关论文
共 50 条
  • [1] Effect of Additional Clostridium butyricum on the Intestinal Flora of Chronic Hepatitis B Patients Treated with Entecavir
    Yu-Xia Lu
    Yi-Zhong Chang
    Ping Liang
    Chang-Qing Yang
    Infectious Diseases and Therapy, 2021, 10 : 1519 - 1530
  • [2] Effect of Clostridium butyricum supplementation on the development of intestinal flora and the immune system of neonatal mice
    Miao, Rui-Xue
    Zhu, Xin-Xin
    Wan, Chao-Min
    Wang, Zhi-Ling
    Wen, Yang
    Li, Yi-Yuan
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2018, 15 (01) : 1081 - 1086
  • [3] Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir
    Fong, Tse-Ling
    Tien, Andy
    Jo, Kahee J.
    Chu, Danny
    Cheung, Eddie
    Mena, Edward A.
    Quang-Quoc Phan
    Yu, Andy S.
    Mohammed, Wafa
    Velasco, Andrew
    Vinh-Huy LeDuc
    Nguyen, Nickolas
    Han, Steven-Bui
    Chang, Mimi
    Bae, Ho S.
    Cho, Yong-Won
    Tong, Myron J.
    Cooper, Stewart L.
    DIGESTIVE DISEASES AND SCIENCES, 2015, 60 (11) : 3465 - 3472
  • [4] The Effect of Entecavir Therapy on Immune Status in Chronic Hepatitis B Patients
    Yan, Huimin
    Zhang, Xinyu
    Lv, Ying
    IRANIAN JOURNAL OF IMMUNOLOGY, 2019, 16 (01) : 84 - 91
  • [5] Histological outcome for chronic hepatitis B patients treated with entecavir vs lamivudine-based therapy
    Jia-Li Wang
    Xin-Fang Du
    Shao-Long Chen
    Yi-Qi Yu
    Jing Wang
    Xi-Qi Hu
    Ling-Yun Shao
    Jia-Zhen Chen
    Xin-Hua Weng
    Wen-Hong Zhang
    World Journal of Gastroenterology, 2015, 21 (32) : 9598 - 9606
  • [6] Histological outcome for chronic hepatitis B patients treated with entecavir vs lamivudine-based therapy
    Wang, Jia-Li
    Du, Xin-Fang
    Chen, Shao-Long
    Yu, Yi-Qi
    Wang, Jing
    Hu, Xi-Qi
    Shao, Ling-Yun
    Chen, Jia-Zhen
    Weng, Xin-Hua
    Zhang, Wen-Hong
    WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (32) : 9598 - 9606
  • [7] Comparable Incidence of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir
    Jung Woo Shin
    Joonho Jeong
    Seok Won Jung
    Seung Bum Lee
    Bo Ryung Park
    Min-Ju Kim
    Eun Ji Park
    Neung Hwa Park
    Digestive Diseases and Sciences, 2021, 66 : 1739 - 1750
  • [8] Virologic response maintenance and hepatocellular carcinoma in chronic hepatitis B patients treated with entecavir
    Wang, Xiaomo
    Chen, Yu
    Xu, Manman
    Cheng, Kailiang
    Duan, Xiaoman
    Liao, Wei
    Wang, Yanhong
    Lu, Ying
    Duan, Zhongping
    Wang, Li
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 15 (11) : 1337 - 1344
  • [9] Comparable Incidence of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir
    Shin, Jung Woo
    Jeong, Joonho
    Jung, Seok Won
    Lee, Seung Bum
    Park, Bo Ryung
    Kim, Min-Ju
    Park, Eun Ji
    Park, Neung Hwa
    DIGESTIVE DISEASES AND SCIENCES, 2021, 66 (05) : 1739 - 1750
  • [10] Development and validation of a model for hepatitis B e antigen seroconversion in entecavir-treated patients with chronic hepatitis B
    Shen, Sheng
    Wong, Grace L. H.
    Kuang, Zhe
    van Campenhout, Margo J. H.
    Fan, Rong
    Wong, Vincent W. S.
    Yip, Terry C. F.
    Chi, Heng
    Liang, Xieer
    Hu, Xiaoyun
    Lin, Weiyin
    Wu, Yaobo
    Liu, Xiaoju
    Boonstra, Andre
    Hou, Jinlin
    Sun, Jian
    Chan, Henry L. Y.
    JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (08) : 1206 - 1213